Can I Take St. John's Wort with Sermorelin?

What Is Sermorelin and How Does It Work?

Sermorelin acetate is a 29-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the anterior pituitary, stimulating pulsatile release of growth hormone (GH), which in turn triggers hepatic and peripheral synthesis of insulin-like growth factor 1 (IGF-1). Because sermorelin preserves the pituitary's own regulatory feedback loops, it is considered a physiologically gentler approach to GH optimization compared to exogenous recombinant human GH.

Route of Administration and Pharmacokinetics

Sermorelin is delivered by subcutaneous injection, typically at doses of 0.2 to 0.3 mg nightly, timed to coincide with endogenous nocturnal GH pulses. After subcutaneous administration, the peptide enters systemic circulation without hepatic first-pass metabolism. Plasma half-life is roughly 10 to 20 minutes due to rapid proteolytic cleavage by serum dipeptidyl peptidases. The short half-life means sermorelin itself is unlikely to be a substrate for CYP450 enzymes in the traditional sense.

Why the CYP3A4 Question Still Matters

Even though sermorelin is not a classic CYP3A4 substrate, this does not make herb-drug interaction concerns irrelevant. Sermorelin's therapeutic benefit depends entirely on the downstream GH/IGF-1 cascade. Any co-administered compound that disrupts somatotropic signaling, cortisol homeostasis, or thyroid function may reduce the clinical response to sermorelin. St. John's Wort creates risk through multiple pathways, none of which require direct enzymatic competition with the peptide itself.

What Is St. John's Wort and Why Does It Cause So Many Drug Interactions?

St. John's Wort (Hypericum perforatum) is one of the most widely used herbal supplements in the United States, with an estimated 4.4 million adults reporting use in a single 12-month period according to NHANES data reviewed by the National Center for Complementary and Integrative Health (NCCIH/NIH). It is most commonly taken for mild-to-moderate depressive symptoms.

The Hyperforin-CYP3A4 Mechanism

The primary active constituent responsible for drug interactions is hyperforin. Hyperforin activates the pregnane X receptor (PXR), a nuclear receptor that transcriptionally upregulates CYP3A4, CYP2C9, and P-glycoprotein (P-gp) expression in the intestinal wall and liver. A landmark clinical pharmacology study published in the New England Journal of Medicine (Piscitelli et al., 2000) demonstrated that St. John's Wort reduced plasma indinavir AUC by 57% through CYP3A4 induction, prompting an FDA public health advisory (FDA advisory) [1].

CYP3A4 induction by St. John's Wort is not a fast-on, fast-off effect. Enzyme upregulation develops over 7 to 14 days of regular use, and the induced state persists for roughly the same period after discontinuation [2].

P-gp Induction as a Second Mechanism

P-glycoprotein is an efflux transporter in intestinal epithelial cells that pumps drugs back into the gut lumen, reducing oral bioavailability. St. John's Wort upregulates P-gp in parallel with CYP3A4 through the same PXR pathway. For orally administered drugs that are P-gp substrates, this means a compounding reduction in systemic exposure. Sermorelin is injected subcutaneously rather than taken orally, so P-gp induction has minimal direct relevance to sermorelin pharmacokinetics specifically, but it matters greatly for any co-prescribed oral medications in the patient's regimen.

Does St. John's Wort Directly Interact with Sermorelin Pharmacokinetically?

No direct pharmacokinetic interaction between sermorelin and St. John's Wort has been reported in peer-reviewed literature. Sermorelin is a small peptide cleared rapidly by proteolytic enzymes in plasma, not by hepatic CYP450 oxidation. That distinction means classic CYP3A4-mediated drug interactions do not apply to the peptide's own clearance.

What the Evidence Actually Shows

The absence of a direct pharmacokinetic interaction does not equal safety. The relevant risks are pharmacodynamic, meaning they affect the biological response to sermorelin rather than its plasma concentrations.

Three pharmacodynamic concerns are worth examining in sequence.

1. HPA-axis effects of hyperforin. Several human trials have investigated the effect of St. John's Wort on cortisol and the hypothalamic-pituitary-adrenal (HPA) axis. A trial by Murck et al. (2002) published in Pharmacopsychiatry found that Hypericum extract WS 5570 altered nocturnal cortisol profiles in healthy volunteers (PubMed) [3]. Cortisol is a physiological antagonist of GH secretion. Elevated or dysregulated cortisol at night, precisely when sermorelin stimulates peak GH release, could dampen pituitary responsiveness to GHRH-receptor agonism.

2. Serotonergic modulation and GH pulsatility. St. John's Wort inhibits reuptake of serotonin, dopamine, and norepinephrine. Serotonergic tone is a known positive modulator of GH secretion, with 5-HT2C receptor activation stimulating hypothalamic GHRH release. Chronic serotonin reuptake inhibition by St. John's Wort could theoretically alter baseline GHRH-pulsatility patterns, creating a less predictable background against which sermorelin acts. No clinical trial has tested this combination directly, and the net directional effect is uncertain.

3. Thyroid hormone metabolism. Case reports and small pharmacokinetic studies suggest St. John's Wort may modestly accelerate the clearance of levothyroxine via CYP3A4 and P-gp induction (PubMed) [4]. Thyroid hormone is a permissive factor for GH secretion. Subclinical hypothyroidism, even mild reduction in free T4, reduces pituitary GH output and blunts IGF-1 generation. Patients on thyroid replacement therapy who begin St. John's Wort may silently drift toward inadequate thyroid coverage, indirectly reducing sermorelin's effectiveness.

Interaction Classification and Risk Level

The table below outlines how the sermorelin plus St. John's Wort combination maps across standard interaction classification frameworks. Neither the Natural Medicines Database nor the FDA has issued a formal contraindication specifically for this peptide-herb pair, in part because sermorelin is a 503A compounded product with limited post-market pharmacovigilance infrastructure. The clinical reasoning, however, supports at minimum a "use with caution and monitor" classification.

| Interaction Domain | Risk Present? | Mechanism | Clinical Significance | |---|---|---|---| | Direct CYP3A4 metabolism of sermorelin | No | Peptide cleared by proteases | None | | P-gp efflux of sermorelin | No | Subcutaneous route, not oral | None | | HPA-axis / cortisol disruption | Possible | Hyperforin, PXR activation | Moderate | | Serotonergic GH-axis modulation | Possible | SRI activity of St. John's Wort | Low-to-moderate | | Thyroid hormone clearance (if on T4) | Yes | CYP3A4/P-gp induction | Moderate (for concurrent T4 users) | | Co-prescribed oral drug interactions | Yes | Broad CYP3A4 induction | High (drug-specific) |

The most clinically significant scenario is a patient taking sermorelin alongside oral medications that are genuine CYP3A4 substrates, such as testosterone cypionate formulations with oral adjuncts, anastrozole, or clonazepam. St. John's Wort's induction profile could meaningfully reduce exposure to those agents while sermorelin's own plasma levels remain unaffected.

Who Is Most at Risk?

Not every person on sermorelin faces the same level of concern from adding St. John's Wort.

Patients on Multi-Drug Hormone Protocols

Telehealth-based hormone optimization protocols rarely consist of sermorelin alone. A typical male patient might be on testosterone cypionate, anastrozole (an aromatase inhibitor and CYP3A4 substrate), and potentially clonazepam or a sleep aid to deepen slow-wave sleep. Anastrozole is metabolized in part via CYP3A4. A pharmacokinetic study by Dowsett et al. Confirmed the CYP3A4 involvement in anastrozole disposition (PubMed) [5]. Adding St. John's Wort to a protocol containing anastrozole could reduce anastrozole plasma levels, allowing estradiol to rise above target range and potentially offsetting the benefits of the combined testosterone-sermorelin treatment.

Patients with Pre-Existing Mood Disorders

Patients using St. John's Wort for depression or anxiety already have an altered neuroendocrine baseline. GH secretion is consistently lower in individuals with major depressive disorder compared to age-matched controls, as shown in a meta-analysis of 13 studies by Bhagya et al. (PubMed) [6]. Sermorelin in this population may produce a smaller IGF-1 response than in euthymic individuals, making careful monitoring especially important.

Patients on Thyroid Replacement

Any patient taking levothyroxine who adds St. John's Wort should have TSH, free T4, and free T3 re-checked within 6 to 8 weeks. The thyroid-GH axis connection is direct: per Endocrine Society guidelines, untreated or undertreated hypothyroidism must be corrected before GH-axis therapy is initiated or assessed (Endocrine Society Clinical Practice Guideline) [7].

What Should You Do If You Are Already Taking Both?

If you are currently taking St. John's Wort and have been prescribed sermorelin, the appropriate first step is disclosure to your prescribing clinician before changing anything unilaterally.

Step 1: Tell Your Clinician Before Stopping St. John's Wort

Abrupt discontinuation of St. John's Wort in a patient who has been using it for mood support carries a non-trivial risk of worsening depressive symptoms. Your clinician should either arrange a supervised taper or coordinate with a mental health provider to substitute a prescription antidepressant if warranted.

Step 2: Get a Baseline IGF-1 Panel

If you have been on sermorelin while also taking St. John's Wort without disclosing the combination, request an IGF-1 and IGFBP-3 panel now. Comparing this result to your pre-sermorelin baseline (if available) will clarify whether the expected IGF-1 rise has occurred. Target IGF-1 ranges for adults on GHRH analog therapy typically fall between the 50th and 75th percentile for age and sex, as outlined in peer-reviewed growth hormone consensus guidelines (PubMed) [8].

Step 3: Allow a 2-Week Washout Before Re-Evaluating Response

CYP3A4 enzyme levels return to baseline roughly 14 days after St. John's Wort discontinuation. After that washout, re-check IGF-1 if your initial result was suboptimal. Any co-prescribed CYP3A4-sensitive oral medications should also be re-assessed for dose appropriateness at the same time point.

Step 4: Explore Evidence-Based Alternatives for the Underlying Indication

If mood support is the reason for St. John's Wort use, there are prescription and non-prescription options with cleaner interaction profiles in the context of a hormone protocol. Your clinician can discuss these based on your individual presentation.

Dose Separation: Will It Help Here?

For supplements that interact through direct enzymatic competition, separating the doses by several hours can reduce the magnitude of interaction. St. John's Wort does not work that way. Because its mechanism is transcriptional upregulation of enzyme expression, CYP3A4 induction is active 24 hours a day regardless of when the last dose of St. John's Wort was taken. Dose separation provides no meaningful protection in this case. Full avoidance or supervised discontinuation is the appropriate management approach.

Monitoring Parameters If Combination Cannot Be Avoided

Occasionally, a patient's clinical situation makes immediate discontinuation of St. John's Wort impractical. In those cases, more frequent monitoring becomes necessary.

Recommended monitoring parameters include:

• IGF-1 and IGFBP-3 at weeks 4, 8, and 12 of combined use
• TSH and free T4 at 6 weeks if the patient is also on levothyroxine
• Estradiol and total testosterone at 6 weeks if the patient is on anastrozole concurrently
• Sleep-quality self-report or validated instrument (PSQI score) to assess whether nocturnal GH pulsatility is being blunted clinically
• PHQ-9 or equivalent mood screen if St. John's Wort is being tapered

The FDA MedWatch program should be consulted for any reporting obligations if an unexpected adverse event occurs (FDA MedWatch) [9].

What the Guidelines Say About Herbal Supplements and Peptide Therapy

Neither the Endocrine Society nor the American Association of Clinical Endocrinology (AACE) has issued specific guidance on herbal supplement interactions with GHRH analogs, reflecting the limited post-market data on compounded 503A peptides. The AACE Growth Hormone Deficiency Task Force does, however, state that "all medications and supplements should be reviewed prior to initiating growth hormone axis therapy, as several drug classes are known to attenuate the GH/IGF-1 response" (AACE) [10].

The Natural Medicines Database classifies St. John's Wort as having a "major" interaction profile with CYP3A4 substrates broadly. While sermorelin is not listed as a named substrate in that database, the clinical rationale for caution in complex multi-drug hormone protocols is well-supported by the general interaction evidence.

As the FDA noted in its 2000 public health advisory on St. John's Wort: "Health care providers should alert patients about these potential drug interactions to prevent treatment failures." [1] That advisory was written in the context of antiretroviral therapy, but the PXR-mediated induction mechanism is not drug-class-specific.

Key Takeaways for Patients and Clinicians

St. John's Wort does not directly compete with sermorelin acetate at the enzyme level. Sermorelin's peptide structure and subcutaneous delivery place it outside the typical CYP3A4-interaction framework.

The concern is indirect but real. Hyperforin-driven CYP3A4 induction can undermine the effectiveness of co-prescribed oral agents in a hormone protocol. Nocturnal cortisol and serotonergic effects may blunt pituitary GH responsiveness. Thyroid hormone clearance acceleration can silently reduce the permissive conditions sermorelin requires.

Disclose all supplements to your prescribing physician before starting sermorelin. Patients already on both should request IGF-1 lab work and a protocol review rather than making independent changes.